{
  "metadata": {
    "case_id": 38,
    "model": "Claude-4.5-Sonnet",
    "timestamp": "2025-11-29T16:00:04.409307",
    "total_alignments": 2,
    "target_section": "protocolSection",
    "ground_truth_path": "/{YOURPATH}/samples/CTG/protocolSection/1_100/38_NCT03337724.json",
    "prediction_path": "/{YOURPATH}/restructured_outputs_protocol/Claude-4.5-Sonnet/38_Claude-4.5-Sonnet.json",
    "shard_range": "1_100"
  },
  "alignments": [
    {
      "field_path": "protocolSection.armsInterventionsModule.armGroups",
      "algorithm": "hungarian",
      "ref_count": 2,
      "pred_count": 2,
      "similarity_matrix": [
        [
          0.98,
          0.7
        ],
        [
          0.6,
          0.9
        ]
      ],
      "matched_pairs": [
        {
          "ref_idx": 0,
          "pred_idx": 0,
          "score": 0.98,
          "status": "matched",
          "ref_item": {
            "label": "Ipatasertib + Paclitaxel",
            "type": "EXPERIMENTAL",
            "interventionNames": [
              "Drug: Ipatasertib",
              "Drug: Paclitaxel"
            ]
          },
          "pred_item": {
            "label": "Ipatasertib + Paclitaxel",
            "type": "EXPERIMENTAL",
            "description": "Patients received oral ipatasertib 400 mg daily on days 1-21 plus intravenous paclitaxel 80 mg/m² on days 1, 8, and 15 of a 28-day cycle until disease progression or unacceptable toxicity",
            "interventionNames": [
              "Drug: Ipatasertib",
              "Drug: Paclitaxel"
            ]
          }
        },
        {
          "ref_idx": 1,
          "pred_idx": 1,
          "score": 0.9,
          "status": "matched",
          "ref_item": {
            "label": "Placebo + Paclitaxel",
            "type": "EXPERIMENTAL",
            "interventionNames": [
              "Drug: Paclitaxel",
              "Drug: Placebo"
            ]
          },
          "pred_item": {
            "label": "Placebo + Paclitaxel",
            "type": "PLACEBO_COMPARATOR",
            "description": "Patients received oral placebo daily on days 1-21 plus intravenous paclitaxel 80 mg/m² on days 1, 8, and 15 of a 28-day cycle until disease progression or unacceptable toxicity",
            "interventionNames": [
              "Drug: Placebo",
              "Drug: Paclitaxel"
            ]
          }
        }
      ]
    },
    {
      "field_path": "protocolSection.armsInterventionsModule.interventions",
      "algorithm": "hungarian",
      "ref_count": 3,
      "pred_count": 3,
      "similarity_matrix": [
        [
          0.98,
          0.4,
          0.35
        ],
        [
          0.4,
          0.3,
          0.99
        ],
        [
          0.4,
          0.97,
          0.4
        ]
      ],
      "matched_pairs": [
        {
          "ref_idx": 0,
          "pred_idx": 0,
          "score": 0.98,
          "status": "matched",
          "ref_item": {
            "type": "DRUG",
            "name": "Ipatasertib",
            "description": "Ipatasertib, 400 milligrams (mg), administered orally once a day (QD) on Days 1-21 of each 28-day cycle until disease progression, intolerable toxicity, elective withdrawal from the study, or study completion or termination.",
            "armGroupLabels": [
              "Ipatasertib + Paclitaxel"
            ]
          },
          "pred_item": {
            "type": "DRUG",
            "name": "Ipatasertib",
            "description": "Oral ATP-competitive small-molecule inhibitor of all three AKT isoforms, administered at 400 mg daily on days 1-21 of each 28-day cycle",
            "armGroupLabels": [
              "Ipatasertib + Paclitaxel"
            ]
          }
        },
        {
          "ref_idx": 1,
          "pred_idx": 2,
          "score": 0.99,
          "status": "matched",
          "ref_item": {
            "type": "DRUG",
            "name": "Paclitaxel",
            "description": "Paclitaxel, 80 mg/square meter (m\\^2), administered intravenously (IV) on Days 1, 8, and 15 of each 28-day cycle until disease progression, intolerable toxicity, elective withdrawal from the study, or study completion or termination.",
            "armGroupLabels": [
              "Ipatasertib + Paclitaxel",
              "Placebo + Paclitaxel"
            ]
          },
          "pred_item": {
            "type": "DRUG",
            "name": "Paclitaxel",
            "description": "Intravenous paclitaxel administered at 80 mg/m² on days 1, 8, and 15 of each 28-day cycle",
            "armGroupLabels": [
              "Ipatasertib + Paclitaxel",
              "Placebo + Paclitaxel"
            ]
          }
        },
        {
          "ref_idx": 2,
          "pred_idx": 1,
          "score": 0.97,
          "status": "matched",
          "ref_item": {
            "type": "DRUG",
            "name": "Placebo",
            "description": "Matching placebo, administered orally QD on Days 1-21 of each 28-day cycle until disease progression, intolerable toxicity, elective withdrawal from the study, or study completion or termination.",
            "armGroupLabels": [
              "Placebo + Paclitaxel"
            ]
          },
          "pred_item": {
            "type": "DRUG",
            "name": "Placebo",
            "description": "Oral placebo administered daily on days 1-21 of each 28-day cycle",
            "armGroupLabels": [
              "Placebo + Paclitaxel"
            ]
          }
        }
      ]
    }
  ]
}